Clinical Trial

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Study acronym: GRABS-0
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI \> 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who continue with the current standard of care for patients who have previously undergone Gastric Bypass Surgery.
Protocol Amendment History 3 changes
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-08-05
critical Primary endpoint(s) modified 2026-06-04
notable Primary completion moved earlier: 2027-05 -> 2027-01-01 2026-05-20
Trial Details
NCT Number NCT06162715
Lead Sponsor Vanderbilt University Medical Center
Conditions Severe Obesity, Obesity, BMI Greater Than 30
Enrollment 30 participants
Start Date 2024-10-30
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-04